reports
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
TWI TITAN INTERNATIONAL INC.
TNET TRINET GROUP INC.
RYI RYERSON HOLDING CORPORATION
PZZA PAPA JOHN'S INTERNATIONAL INC.
PII POLARIS INC.
J7Z JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
JACK JACK IN THE BOX INC.
HURN HURON CONSULTING GROUP INC.
FIVE FIVE BELOW INC.
EXTR EXTREME NETWORKS INC.
EXPE EXPEDIA GROUP INC.
EXEL EXELIXIS INC.
EXAS EXACT SCIENCES CORPORATION
EVH EVOLENT HEALTH INC CLASS A
CLX CLOROX COMPANY
ACAD ACADIA PHARMACEUTICALS INC.
BF.B BROWN-FORMAN CORPORATION CLASS B
COHU COHU INC.
IONS IONIS PHARMACEUTICALS INC.
LEG LEGGETT & PLATT INCORPORATED
TAP MOLSON COORS BEVERAGE COMPANY CLASS B
THS TREEHOUSE FOODS INC.
WH WYNDHAM HOTELS & RESORTS INC.
BMY BRISTOL-MYERS SQUIBB CO. CEDEAR
SUZBY SUZANO SA
PGNY PROGYNY
ODP THE ODP CORPORATION
APA APA CORPORATION
PTLO PORTILLOS INC
STVN STEVANATO GRP SPA
FNA PARAGON 28 INC
SHLS SAKHALIN SHIPPING CO ORD
P RAILPOWER TECHNOLOGIES CORP COM
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a C...
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024 MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the completion of the last patient’s final visit in the Company’s Phase 1b/2a clini...
Five Below, Inc. Announces First Quarter Fiscal 2024 Earnings Release ...
Five Below, Inc. Announces First Quarter Fiscal 2024 Earnings Release and Conference Call Date PHILADELPHIA, PA, May 15, 2024 (GLOBE NEWSWIRE) -- Five Below, Inc. (NASDAQ: FIVE), the trend-right, high-quality, extreme-value retailer for tweens, teens and beyond, today announced that its financial results for the first quarter of fiscal 2024 will be released after market close on Wednesday, June 5, 2024. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 412-...
Avenue Therapeutics Reports First Quarter 2024 Financial Results and R...
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights – Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2024. “The first quarter was incredib...
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA ...
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Data highlighting this historic manufacturing milestone are being presented today in a Spotlight Presentation at the TIDES USA annual meeting taking place in Boston, MA, and virtually May 14 – 17, 2024. “The data presented today by Codexis are t...
HF Foods Reports First Quarter 2024 Financial Results
HF Foods Reports First Quarter 2024 Financial Results Highest Net Revenue Ever Recorded During First Quarter of $295.7 Million Pre-Recorded Earnings Call Webcast Available on Investor Relations Website LAS VEGAS, May 08, 2024 (GLOBE NEWSWIRE) -- HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods”, or the “Company”), a leading food distributor to Asian restaurants across the United States, reported unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net revenue increased 0.6% to $295.7 million compared to $293.9 million in the...
Codexis Reports First Quarter 2024 Financial Results
Codexis Reports First Quarter 2024 Financial Results Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer Company is in Final Stages of Enzymatically Synthesizing a Full-Length Oligonucleotide with ECO Synthesis™ Manufacturing Platform and will Provide Update at TIDES USA Meeting REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the first...
- Brian Gordon
- Budd Bugatch
Culp to Restructure Mattress Division, Eliminate Excess Capacity, Give...
After Wednesday’s market close, Culp announced aggressive actions to ‘right-size’ capacity in CHF, its Culp Home Fashions (CHF) segment. CHF is the market leader and serves the mattress/bedding fabric market. In the face of persisting weak end market demand for mattresses, Culp initiated restructuring initiatives to right-size CHF capacity to match industry conditions for the foreseeable future. These actions will evolve during FY25 (began May). The bulk of the ~$8MM in planned restructuring cha...
HF Foods To Participate in the Sidoti Micro Cap Conference
HF Foods To Participate in the Sidoti Micro Cap Conference LAS VEGAS, May 01, 2024 (GLOBE NEWSWIRE) -- HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods” or the “Company”), a leading food distributor to Asian restaurants across the United States, today announced that the Company will be participating virtually in the Sidoti Micro Cap Conference. The HF Foods executive management team is hosting a presentation that is scheduled to begin at 4:00 p.m. ET on Wednesday, May 8, 2024. The presentation will be webcast live and made available through the “Events” section of the Company’s Investor Rel...
HF Foods to Report First Quarter 2024 Results on May 8, 2024
HF Foods to Report First Quarter 2024 Results on May 8, 2024 Pre-Recorded Earnings Call Webcast Will Be Available on Investor Relations Website LAS VEGAS, May 01, 2024 (GLOBE NEWSWIRE) -- HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods”, or the “Company”), a leading food distributor to Asian restaurants across the United States, today announced it will report financial results for the first quarter ended March 31, 2024, on Wednesday, May 8, 2024, before market open. Prepared remarks from members of the executive management team discussing these results with additional comments and detail...
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in...
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 689,680 shares of the Company’s common stock. The exercised warrants are comprised of warrants to purchase shares of c...
HF Foods Appoints Cindy Yao as Chief Financial Officer
HF Foods Appoints Cindy Yao as Chief Financial Officer LAS VEGAS, April 25, 2024 (GLOBE NEWSWIRE) -- HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods”, or the “Company”), a leading food distributor to Asian restaurants across the United States, today announced that Cindy Yao has been named Chief Financial Officer, effective May 1, 2024. “Cindy's extensive experience, especially having spent a decade directing financial operations for a company serving food producers, makes her an invaluable addition to HF Foods,” said Peter Zhang, Chief Executive Officer of HF Foods. “Her proven track rec...
Avenue Therapeutics Announces Reverse Stock Split
Avenue Therapeutics Announces Reverse Stock Split MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will effect a 1-for-75 reverse split of its issued and outstanding common stock. Avenue expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on April 26, 2024 with a new CUSIP number of 05360L...
Codexis to Report First Quarter 2024 Financial Results on May 2
Codexis to Report First Quarter 2024 Financial Results on May 2 REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on Thursday, May 2, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access the live webcast on the , where it will be archived for 90 days. The live call ...
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platform REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agriculture and pharmaceutical appl...
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on ...
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event will focus o...
Five Below, Inc. Announces Fourth Quarter and Fiscal 2023 Financial Re...
Five Below, Inc. Announces Fourth Quarter and Fiscal 2023 Financial Results Q4 Net Sales Increase of 19% with a Comparable Sales Increase of 3.1%; Q4 EPS Increase of 19% Fiscal 2023 Net Sales Increase of 16% with a Comparable Sales Increase of 2.8%; Fiscal 2023 EPS Increase of 15% Provides First Quarter and Fiscal 2024 Guidance PHILADELPHIA, PA, March 20, 2024 (GLOBE NEWSWIRE) -- Five Below, Inc. (NASDAQ: FIVE) today announced financial results for the fourth quarter and full year of fiscal 2023 ended February 3, 2024, both of which contained one additional week ("53rd week") versus th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.